Formulary Forum: Intrathecal Ziconotide for Refractory Chronic Pain

@article{Lynch2006FormularyFI,
  title={Formulary Forum: Intrathecal Ziconotide for Refractory Chronic Pain},
  author={S. Lynch and Christine M. Cheng and J. Yee},
  journal={Annals of Pharmacotherapy},
  year={2006},
  volume={40},
  pages={1293 - 1300}
}
Objective: TO describe the pharmacology, efficacy, and safety of ziconotide for treatment of severe chronic pain in patients who are candidates for intrathecal therapy. Data Sources: A PubMed/MEDLINE search (1966–June 2006) was conducted using the terms ziconotide, Priait, and SNX-111. Manufacturer-provided data, the Food and Drug Administration medical review of ziconotide, and abstracts presented at American Pain Society meetings (2001–2006) were also reviewed. Study Selection and Data… Expand
Ziconotide for treatment of severe chronic pain
TLDR
An overview of the benefits and limitations of intrathecal ziconotide treatment is provided and potential future developments in this new drug class of selective N-type voltage-sensitive calcium-channel blockers are reviewed. Expand
Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain.
TLDR
This systematic review found that there is a lack of evidence for intrathecal infusion systems for long-term relief in chronic non-cancer pain, and the level of evidence indicated either Level II-3 or Level III (limited) based on U.S. Preventive Services Task Force (USPSTF) criteria. Expand
Analgesic and side effects of intravenous recombinant Phα1β
TLDR
Investigation of the possible antinociceptive effect of intravenous recombinant Phα1β in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters, suggest that intravenous administration of Ph α1β may be feasible for drug-induced analgesia, without causing any severe side effects. Expand
Advances in the development of novel analgesics
TLDR
This review focuses on the most recent chemical scaffolds that are being investigated towards advancing selective small molecule cannabinoid agonists (CB2), ion channel modulators (sodium channels, calcium channels, potassium channels, transient receptor potential channels), acid-sensing ion channels and purinergic receptors as well as modulators of the norepinephrine system into the clinic. Expand
Interventional Therapies for Chronic Low Back Pain: A Focused Review (Efficacy and Outcomes)
TLDR
This review article describes the most common modalities available to an interventional pain physician along with the most relevant current and past references for the treatment of lower back pain. Expand
Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management
TLDR
There remains a critical need to improve the convenience of peptide drug delivery methods, and reduce the number and severity of adverse effects associated with ω-conotoxin-based therapies, in the treatment of neuropathic pain. Expand
Pain pharmacology and analgesia
TLDR
In the next decade, a new generation of pain medicines is likely to reach the market, thereby expanding the armamentarium of drugs available to clinicians for the management of persistent on-going pain. Expand
Targeting voltage-gated calcium channels for neuropathic pain management
TLDR
This review included clinical trials aiming to expand the application of approved VGCC drugs to different pain states derived from various pathological conditions, as well as drug combination therapies trying to improve the efficacies and side-effect profiles of current pain medications. Expand
Efficacy and Safety of Intrathecal Ziconotide forthe Management of Chronic Pain. A SystematicReview of the Literature and Meta-Analysis ofRandomized, Placebo-Controlled Trials
1Department of Neuroscience, Faculty of Medicine, Hospital Universitario San Ignacio – Pontificia Universidad Javeriana, Bogotá D.C, Colombia 2Neurosurgery Department, Faculty of Medicine, PontificiaExpand
Cancer pain management in the 21st century.
TLDR
This manuscript reviews progress in cancer pain management during the past 2 decades and concludes that an effective strategy to make alleviating pain a major health-care priority remains the primary challenge to effectively palliating patients with cancer pain. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.
TLDR
Intrathecal ziconotide provided clinically and statistically significant analgesia in patients with pain from cancer or AIDS, with no loss of efficacy of ziconite in the maintenance phase. Expand
Pharmacokinetics and Pharmacodynamics of Intrathecal Ziconotide in Chronic Pain Patients
TLDR
Higher CSF ziconotide concentrations were generally associated with analgesia and increased incidence of nervous system adverse events following a 1‐hour IT infusion, and pharmacokinetic‐pharmacodynamic efficacy and safety analyses showed. Expand
A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
TLDR
Slow titration of ziconotide, a nonopioid analgesic, to a low maximum dose resulted in significant improvement in pain and was better tolerated than in two previous controlled trials that used a faster titration to a higher mean dose. Expand
Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel.
TLDR
A Polyanalgesic Consensus Conference 2003 was organized to review the literature on intraspinal drug infusion and develop guidelines for optimizing drug dosage and concentration and to clarify issues pertaining to compounding of drugs. Expand
The undertreatment of pain in ambulatory AIDS patients
TLDR
The alarming degree of undertreatment of pain in ambulatory patients with AIDS is demonstrated, and the need to improve the management of AIDS‐related pain in this underserved population is indicated. Expand
Voltage‐Gated Calcium Channels as Targets for the Treatment of Chronic Pain
TLDR
How the major genetic, functional, and pharmacological differences between subtypes of neuronal calcium channels can be leveraged to identify new molecular targets and to discover and develop new therapeutic agents for the treatment of chronic pain syndromes is discussed. Expand
Pain and Its Management in Animals
TLDR
Although the selection and techniques of administration of individual analgesic drugs vary, local and opioid analgesics, non-steroidal anti-inflammatory drugs, tranquilizers and other combination therapies when used appropriately can control pain and alleviate suffering in animals experiencing pain. Expand
Chronic pain management in the surgical patient.
TLDR
Managing surgical patients who have chronic pain that results from their surgical disease and its treatment can bring a new and rewarding dimension to surgical practice and overcome a sense of abandonment that may accompany the discharge of a patient who is not healed fully. Expand
Are nursing home patients with dementia diagnosis at increased risk for inadequate pain treatment?
TLDR
The aim was to examine pain assessment and complaints and pain treatment of nursing home patients according to mental state, and with special regard to treatment of patients with dementia diagnosis and cognitively impaired patients who did not have a dementia diagnosis. Expand
A Consensus Statement Regarding the Present Suggested Titration for Prialt (Ziconotide)
...
1
2
3
...